Controle glycemique avant et apres sitagliptine en medecine generale: analyse des facteurs determinants dans l'etude observationnelle belge "SUGAR". ; Glycaemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR".

peer reviewed ; Sitagliptin (Januvia), the first selective inhibitor of dipeptidylpeptidase-4 with a so-called incretin effect, has been evaluated in SUGAR, a large Belgian prospective observational study carried out in general practice. Sitagliptin, at a dose of 100 mg once daily, was added to previous treatment of not well controlled type 2 diabetic patients (> 95% on metformin monotherapy). Among 605 patients analysed in intention to treat, the worse the glycaemic control at entry, the greatest the reduction in glycated haemoglobin (HbA1c) and fasting plasma glucose levels after the addi... Mehr ...